A large-scale study by British researchers has revealed that a daily, low-dose aspirin regimen could slash the risk of cancer death by between ten and sixty percent.
The study included more than 25,000 patients and aimed to measure the impact of daily aspirin use on cardiovascular health. The “exciting and potentially findings” were published in the December 7th online edition of the medical journal The Lancet, where researchers were quoted as saying:
“Daily aspirin reduced deaths due to several common cancers during and after the trials… Benefit increased with duration of treatment and was consistent across the different study populations. These findings have implications for guidelines on use of aspirin and for understanding of carcinogenesis and its susceptibility to drug intervention.”
Dr. Alan Arslan, an assistant professor at New York University, said the findings were “very significant,” but cautioned patients to discuss an aspirin regimen with a doctor:
“The take-home message for patients is that if someone is taking low-dose or regular aspirin, it may put them at a reduced risk of death from cancer,” Arslan added. “However, if someone is not already taking aspirin they should talk with their physician before starting. Aspirin has risks of side effects, including bleeding and stroke.”